Virtu Financial LLC Sells 47,031 Shares of Tonix Pharmaceuticals Holding Corp. $TNXP

Key Points

• Virtu Financial LLC has significantly reduced its holdings in Tonix Pharmaceuticals by 73.6%, now owning approximately 16,878 shares worth about $302,000.
• Tonix Pharmaceuticals reported a net loss of ($3.86) per share for its latest quarter, missing expectations and reflecting a negative return on equity of 57.93%.
• Analysts have recently upgraded the company's stock rating from “sell” to “hold”, while another firm reiterated a “buy” rating, indicating mixed sentiments on future performance.

Virtu Financial LLC reduced its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) by 73.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,878 shares of the company's stock after selling 47,031 shares during the period. Virtu Financial LLC owned approximately 0.26% of Tonix Pharmaceuticals worth $302,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in TNXP. Two Sigma Investments LP purchased a new position in Tonix Pharmaceuticals in the fourth quarter worth $66,000. Northern Trust Corp purchased a new position in Tonix Pharmaceuticals in the fourth quarter worth $162,000. IFP Advisors Inc purchased a new position in Tonix Pharmaceuticals in the first quarter worth $179,000. Rhumbline Advisers purchased a new position in Tonix Pharmaceuticals in the first quarter worth $244,000. Finally, Point72 Asset Management L.P. purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at about $526,000. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Trading Down 8.8%

TNXP traded down $3.54 during midday trading on Tuesday, reaching $36.53. The company's stock had a trading volume of 2,865,702 shares, compared to its average volume of 1,404,156. The firm has a market capitalization of $320.37 million, a price-to-earnings ratio of -0.93 and a beta of 1.70. Tonix Pharmaceuticals Holding Corp. has a 1 year low of $6.76 and a 1 year high of $130.00. The stock's 50-day moving average is $41.39 and its 200-day moving average is $27.16.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($3.86) earnings per share for the quarter, missing analysts' consensus estimates of ($3.10) by ($0.76). The business had revenue of $2.00 million during the quarter, compared to analysts' expectations of $2.60 million. Tonix Pharmaceuticals had a negative return on equity of 57.93% and a negative net margin of 828.22%. As a group, equities research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on TNXP. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Alliance Global Partners reaffirmed a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $70.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.